These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 35762107)

  • 1. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.
    Megna M; Potestio L; Camela E; Fabbrocini G; Ruggiero A
    Dermatol Ther; 2022 Sep; 35(9):e15667. PubMed ID: 35762107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
    Rigopoulos D; Angelakopoulos C; Apalla Z; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Tampouratzi E; Chasapi V; Sfaelos K; Ioannides D;
    Dermatol Ther; 2022 Dec; 35(12):e15886. PubMed ID: 36184757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.
    Kojanova M; Hugo J; Velackova B; Cetkovska P; Fialova J; Dolezal T; Tichy M; Gkalpakiotis S;
    J Dermatolog Treat; 2022 Sep; 33(6):2827-2837. PubMed ID: 35635185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch.
    Gaudet V; Yap B; Hassan S; Barbeau M
    J Cutan Med Surg; 2023; 27(3):226-235. PubMed ID: 37083148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis.
    Elgaard CDB; Iversen L; Hjuler KF
    Drugs R D; 2023 Jun; 23(2):155-163. PubMed ID: 37155121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
    Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
    Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
    Nyholm N; Schnack H; Danø A; Skowron F
    Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals.
    Tampouratzi E; Papakonstantis M; Katsantonis J; Sidiropoulos T; Delli F; Efthymiadis K; Sfaelos K; Christodoulou A; Chasapi V; Panagakis P
    Dermatol Ther; 2022 Jul; 35(7):e15532. PubMed ID: 35451147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting.
    Demirel Öğüt N; Koç Yıldırım S; Erbağcı E; Hapa FA
    J Cosmet Dermatol; 2022 Nov; 21(11):6215-6224. PubMed ID: 35801372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
    Ruggiero A; Fabbrocini G; Cinelli E; Megna M
    Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years.
    Mastorino L; Dapavo P; Burzi L; Rosset F; Giunipero di Corteranzo I; Leo F; Verrone A; Stroppiana E; Ortoncelli M; Ribero S; Quaglino P
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):568-575. PubMed ID: 38147467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García EA; Herrera-Ceballos E
    Dermatol Ther; 2020 May; 33(3):e13313. PubMed ID: 32181962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience.
    Gönülal M; Altunay İK; Doğan S; Türkmen M; Balcı DD; Öztürkcan S
    Dermatol Ther; 2022 Dec; 35(12):e15955. PubMed ID: 36271759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
    Leonardi CL; See K; Burge R; Sun Z; Zhang Y; Mallbris L; Garrelts A; Warren RB
    Adv Ther; 2022 May; 39(5):2256-2269. PubMed ID: 35316500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
    Fargnoli MC; Esposito M; Dapavo P; Parodi A; Rossi M; Tiberio R; Dastoli S; Offidani AM; Argenziano G; Gisondi P; Lo Schiavo A; Loconsole F; Pella P; Bardazzi F; Cusano F; Gattoni M; Nacca M; Cannavò SP; Pellegrini C; Costanzo A;
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):693-700. PubMed ID: 32916767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.